Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

We investigated the possibility that a proportion of children with sporadic rhabdomyosarcoma (RMS) carry constitutional mutations of the p53 tumor suppressor gene. 33 patients with sporadic RMS at two large outpatient pediatric oncology clinics submitted blood samples. Genomic DNA was extracted from peripheral blood leukocytes and PCR was used to amplify exons 2-11 of the p53 gene. Amplified genomic DNA was screened for the presence of germline p53 mutations using single-strand conformation polymorphism (SSCP) analysis. The DNA sequence of those samples that showed aberrant migration of bands on SSCP analysis was determined to identify the precise nature of the gene mutations. Patient records were reviewed to assess clinical correlates of the mutant p53 carrier state. Heterozygous constitutional mutations were detected in 3/33 patient samples screened. Two of these missense mutations are located in exon 7 and one in exon 8 of the p53 gene. The presence of mutations was not correlated with tumor histology, stage, or site. However, an association between young age at diagnosis and presence of a constitutional p53 mutation was noted: 3/13 children under the age of 3 yr at diagnosis carried mutations, whereas none of 20 children over 3 yr of age at diagnosis harbored a detectable constitutional mutation. These results in children with RMS corroborates previous findings in other clinical settings suggesting that the mutant p53 carrier state may predispose individuals to malignancy at an early age. Although this study did not assess whether the mutations were preexisting or new germline alterations, assessment of close relatives of RMS patients for cancer risk and predictive genetic testing may be indicated.

[1]  J. Fraumeni,et al.  Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. , 1969, Journal of the National Cancer Institute.

[2]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.

[3]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Knudson,et al.  Mutation and cancer: a model for Wilms' tumor of the kidney. , 1972, Journal of the National Cancer Institute.

[5]  B Langholz,et al.  Childhood cancer incidence: Geographical and temporal variations , 1983, International journal of cancer.

[6]  M. Isobe,et al.  Localization of gene for human p53 tumour antigen to band 17p13 , 1986, Nature.

[7]  L. Crawford,et al.  Characterization of the human p53 gene , 1986, Molecular and cellular biology.

[8]  D. Givol,et al.  The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Draper,et al.  Incidence of second primary tumours among childhood cancer survivors. , 1987, British Journal of Cancer.

[10]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[11]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[12]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[13]  S. Donaldson,et al.  An attempt to use a common staging system in rhabdomyosarcoma: a report of an international workshop initiated by the International Society of Pediatric Oncology (SIOP). , 1989, Medical and pediatric oncology.

[14]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[15]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[16]  W. Cavenee,et al.  Mechanisms of p53 loss in human sarcomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Birch,et al.  Malignant disease in the mothers of a population-based series of young adults with bone and soft tissue sarcomas. , 1991, British Journal of Cancer.

[18]  R. Katakura,et al.  Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. , 1991, Oncogene.

[19]  J. Fraumeni,et al.  Follow-up study of twenty-four families with Li-Fraumeni syndrome. , 1991, Cancer research.

[20]  A. Craft,et al.  p53 germline mutations in Li-Fraumeni syndrome , 1991, The Lancet.

[21]  L. Strong,et al.  A germ line mutation in exon 5 of the p53 gene in an extended cancer family. , 1991, Cancer research.

[22]  B. Emanuel,et al.  Localization of the rhabdomyosarcoma t(2;13) breakpoint on a physical map of chromosome 13. , 1991, Genomics.

[23]  V. Sheffield,et al.  Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Carbone,et al.  Polymorphism at codon 213 within the p53 gene. , 1991, Oncogene.

[25]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[26]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[27]  D. Lane,et al.  Abnormal expression of wild type p53 protein in normal cells of a cancer family patient , 1992, The Lancet.

[28]  J. Whang‐Peng,et al.  Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. , 1992, The Journal of clinical investigation.

[29]  S. Friend,et al.  Screening for germ line TP53 mutations in breast cancer patients. , 1992, Cancer research.

[30]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[31]  B. Vogelstein,et al.  Inherited p53 gene mutations in breast cancer. , 1992, Cancer research.

[32]  S. Friend,et al.  Cancer risks from germline p53 mutations. , 1992, The Journal of clinical investigation.

[33]  Cell cycle regulation and the p53 tumor suppressor protein. , 1992 .

[34]  R. Weichselbaum,et al.  Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. , 1992, The New England journal of medicine.

[35]  S. Friend,et al.  Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. , 1992, The New England journal of medicine.

[36]  A. Iavarone,et al.  Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  E. Appella,et al.  Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[39]  J. Yokota,et al.  Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. , 1992, Journal of the National Cancer Institute.

[40]  C. Felix,et al.  Frequency and Diversity of P53 Mutations in Childhood Updated Version Citing Articles E-mail Alerts Frequency and Diversity of P53 Mutations in Childhood Rhabdomyosarcoma , 1992 .

[41]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[42]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[43]  C. Bonaïti‐pellié,et al.  Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. , 1993, Cancer research.

[44]  B. Gallie,et al.  Mutations of the p53 gene do not occur in testis cancer. , 1993, Cancer research.

[45]  P. Meltzer,et al.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas. , 1993, Cancer research.

[46]  M. Oren,et al.  Sequence‐specific DNA binding by p53: identification of target sites and lack of binding to p53 ‐ MDM2 complexes. , 1993, The EMBO journal.

[47]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[48]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[49]  A. Craft,et al.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.

[50]  S. Friend,et al.  Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  C. Portwine,et al.  High frequency of germline p53 mutations in childhood adrenocortical cancer. , 1994, Journal of the National Cancer Institute.